Cargando…
Promoter choice: Who should drive the CAR in T cells?
Chimeric antigen receptor (CAR) T cell therapy is an effective treatment for B cell malignancies, with emerging potential for the treatment of other hematologic cancers and solid tumors. The strength of the promoter within the CAR cassette will alter CAR-polypeptide levels on the cell surface of the...
Autores principales: | Rad S. M., Ali Hosseini, Poudel, Aarati, Tan, Grace Min Yi, McLellan, Alexander D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380635/ https://www.ncbi.nlm.nih.gov/pubmed/32706785 http://dx.doi.org/10.1371/journal.pone.0232915 |
Ejemplares similares
-
Optimisation of Tet-On inducible systems for Sleeping Beauty-based chimeric antigen receptor (CAR) applications
por: Ali Hosseini Rad, S. M., et al.
Publicado: (2020) -
Anti-Apoptotic c-FLIP Reduces the Anti-Tumour Activity of Chimeric Antigen Receptor T Cells
por: Tan, Grace Min Yi, et al.
Publicado: (2022) -
Compact Bidirectional Promoters for Dual-Gene Expression in a Sleeping Beauty Transposon
por: He, Kevin, et al.
Publicado: (2020) -
Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells
por: Rad S. M., Ali Hosseini, et al.
Publicado: (2021) -
Implications of SARS-CoV-2 Mutations for Genomic RNA Structure and Host microRNA Targeting
por: Hosseini Rad SM, Ali, et al.
Publicado: (2020)